Highlights Eterna Therapeutics Inc.

Equities

ERNA

US1140822099

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-29 pm EDT			5-day change	1st Jan Change
1.83 ^USD	+2.24%		-14.49%	+1.95%

Mar. 15	North American Morning Briefing : Inflation -2-	DJ
Mar. 14	Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Eterna Therapeutics Inc. Enter into an Exclusive Amended and Restated License Agreement with Factor Bioscience Limited	Nov. 16	CI
Eterna Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Lineage Cell Therapeutics, Inc. Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership with Eterna Therapeutics	23-09-06	CI
Eterna Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Eterna Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Eterna Therapeutics Lowers Q4 Net Loss by Almost 60%; Shares Up After-Hours	23-03-20	MT
Eterna Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-20	CI
Eterna Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-20	CI
Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Lineage Enters into Option and License Agreement with Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications	23-02-22	CI
Eterna Therapeutics Gets Non-Compliance Notice from Nasdaq	22-11-23	MT
Eterna Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Eterna Therapeutics Inc., Enters into Sublease Agreement with E.R. Squibb & Sons, L.L.C	22-10-24	CI
Eterna Therapeutics Gets Option to License Cancer Treatments From Exacis	22-10-17	MT
Eterna Therapeutics Inc Enters into Option Agreement with Exacis Biotherapeutics Inc	22-10-17	CI
Reverse Split: 1 of 20	22-10-16	FA
Brooklyn ImmunoTherapeutics Discloses Agreement With Factor Bioscience	22-09-15	MT
Eterna Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Eterna Therapeutics Inc.

Equities

ERNA

US1140822099

Highlights

Filters